Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / memo-delaware-law-interested-director-transactions.docx
memo-delaware-law-interested-director-transactions.docx
Parties
Penterra Pharmaceuticals Corp
Harkness LLP
Delaware General Corp
M&F Worldwide Corp
Cole LLP
Thorngate Partners LLC
Ostrander Corp
Whitfield Graves LLP
Dates
June 8, 2023
June 2, 2023
March 31, 2023
February 14, 2023
June 1, 2023
March 8, 2023
April 12, 2023
May 15, 2023
June 16, 2023
December 31, 2026
Amounts
$925
$263,625,000
$221,625,000
$42
$680
$78.4
$112.6
$347
$5.8
$3.2
Obligations
Hale's relationship with Caliston and his interest in the proposed transaction must be fully disclosed to the Special Committee
At minimum, the following information must be disclosed and documented in the Special Committee's records: (a) The nature and extent of Dr
All aspects of the issue must be examined as a whole since the question is one of entire fairness
Courts consider the following key elements in assessing fair dealing: • Timing: When was the transaction initiated, and was the timing calculated to disadvantage the minority? • Independence of Negotiators: Were the persons negotiating on behalf of the corporation independent of the interested party? Were they free from conflicts and able to exercise genuine independent judgment? • Structure of the Process: Was the process structured to ensure arm's-length bargaining? Was a special committee formed? Was the committee empowered to retain independent advisors and to reject the transaction? • Completeness of Disclosure: Were all material facts disclosed to the decision-makers? Were any material facts withheld or presented in a misleading manner? • Exclusion of Interested Parties: Were the interested parties excluded from the negotiation and deliberation process? As applied to the proposed transaction, the Special Committee must be able to demonstrate all of the following in order to establish fair dealing: First, that Dr
Compliance with these restrictions must be maintained throughout the process
The premium analysis must therefore be contextualized against the evolution of Caliston's value drivers and risk profile since the Series C